LOS ANGELES--(BUSINESS WIRE)--April 25, 2005--Regal One Corporation (OTCBB:RONE), as part of its previously announced long-range strategy to invest in promising biomedical companies, has signed an option agreement to acquire a significant stake in SuperOxide Health Sciences, Inc. (SOHS). Assuming full exercise of all rights by Regal One, it may acquire up to 40% of SuperOxide Health Sciences, and has provided the company an incentive to repurchase half of that percentage when SOHS meets certain milestones in increasing the value of its shares to all shareholders. Regal One has delivered its initial investment to SOHS as part of the agreement. SuperOxide Health Sciences is a development stage company that is researching and developing products and processes to treat a number of significant health issues that respond to superoxide ions (oxygen molecules with an added electron), for example asthma and respiratory problems. SOHS has developed a prototype device that produces pure superoxide ions and plans to bring a product to market in the second half of this year.
